<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951013</url>
  </required_header>
  <id_info>
    <org_study_id>PLT20161023</org_study_id>
    <nct_id>NCT02951013</nct_id>
  </id_info>
  <brief_title>Transfusion Strategies for Pediatric Liver Transplantation</brief_title>
  <official_title>The Perioperative Liberal or Restrictive Transfusion in Pediatric Liver Transplantation: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients assigned to the restrictive group will receive transfusion once the hemoglobin&#xD;
      concentration falls below 6.0 g per deciliter, with a target hemoglobin range of 7.5 to 8.0 g&#xD;
      per deciliter. Patients assigned to the liberal group will receive transfusion once the&#xD;
      hemoglobin concentration falls below 8.0 g per deciliter, with a target hemoglobin range of&#xD;
      9.0 to 10.0 g per deciliter.&#xD;
&#xD;
      The primary outcome: Survival rate in six months after randomization.&#xD;
&#xD;
      Secondary outcomes: Incidence of perioperative complications, including sepsis , pulmonary&#xD;
      complications, portal vein thrombosis, hepatic artery thrombosis and transfusion-related&#xD;
      adverse events. Intraoperative blood loss, intraoperative blood transfusion amount,&#xD;
      postoperative blood transfusion amount in 7 days after surgery, postoperative inflammatory&#xD;
      reaction, mechanical ventilation time in the intensive care unit, lengths of stay in the&#xD;
      intensive care unit and the hospitalï¼Œand hospitalization expenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of intraoperative blood transfusion</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of blood transfusion during perioperative period</measure>
    <time_frame>up to 7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial partial pressure of oxygen during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lactic acid concentration during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen uptake rate during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily score on Pediatric end-stage liver disease (PELD) assessment</measure>
    <time_frame>up to 7 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Mechanical Ventilation in the intensive care unit</measure>
    <time_frame>at discharge, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lengths of stay in the intensive care unit</measure>
    <time_frame>at discharge, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who need a second hepatic surgery</measure>
    <time_frame>up to 7 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Days</measure>
    <time_frame>at discharge, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Out of pocket expenditure for hospitalization</measure>
    <time_frame>at discharge, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe postoperative complications before discharge</measure>
    <time_frame>from end of surgery till at discharge, an average of 2 weeks</time_frame>
    <description>Postoperative complications include sepsis , pulmonary complications, portal vein thrombosis, hepatic artery thrombosis and transfusion-related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Pediatric Patients Who Need Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>restrictive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liberal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>restrictive transfusion</intervention_name>
    <description>Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL</description>
    <arm_group_label>restrictive group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liberal transfusion</intervention_name>
    <arm_group_label>liberal group</arm_group_label>
    <other_name>Transfusion will start when the hemoglobin concentration falls below 8.0 g/dL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The investigators study included pediatric patients (the moon's age &lt;36 months) who&#xD;
             will receive standard living-donor liver transplantation (LDLT) in Renji Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria of the study were a congenital sufferer from heart, lung,&#xD;
             kidney, nervous system or blood disease,active Lung infection, a history of liver&#xD;
             transplantation, Multivisceral transplantation, refused to participate the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Tian</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Tian</last_name>
    <phone>862168383702</phone>
    <email>vaseline2001@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital affliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200126</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JIE TIAN, Ph.D</last_name>
      <phone>862168383702</phone>
      <email>vaseline2001@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

